Osimertinib Mesylate Tablets
Osimertinib Mesylate Tablets is a pharmaceutical drug with 9 clinical trials. Currently 5 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
2
Early Stage
6
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
5
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Clinical Trials (9)
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9